...
首页> 外文期刊>Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research >Long-term corticosteroid therapy induces mild changes in trabecular bone texture.
【24h】

Long-term corticosteroid therapy induces mild changes in trabecular bone texture.

机译:长期使用皮质类固醇激素可引起小梁骨质地轻度变化。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The relative roles of bone mineral density (BMD) decrease and of microarchitectural changes in corticosteroid-induced osteoporosis (CIOP) are debated. Our objective has been to evaluate both bone microarchitecture (by a fractal analysis of texture on radiographs) and BMD in corticosteroid (CS)-treated patients. In this study, 60 patients from a rheumatology unit with a mean age of 60.6+/-14.8 years taking CS therapy for more than 6 months and a cumulative dose of prednisone over 1 g and 57 controls among age-matched patients and hospital staff were recruited. Bone diseases and bone-modifying drugs (except calcium, vitamin D, and hormonal replacement therapy [HRT]) were considered as exclusion criteria. A fractal analysis of trabecular bone texture was performed on calcaneus radiographs after an oriented analysis in 18 directions. The fractal analysis was based on the fractional Brownian motion model. Results were expressed by H parameter (H = 2 - fractal dimension) in each direction, Hmean being the average of 18 directions, Hmini the minimum, and Hmaxi the maximum. BMD was measured by double-energy X-ray absorptiometry (DEXA) at the femoral neck (FN) and lumbar spine (LS). The odds ratios (OR) were calculated for a variation of 1 SD. The mean duration and dose of CS therapy was 5.6+/-6.6 years and 16.9+/-19.7 g. CS therapy was significantly correlated to a decrease in FN or LSBMD: OR = 1.95, 95% confidence interval (CI, 1.29-2.97) and OR = 3.19 (CI, 1.80-5.66), respectively. The Hmean and Hmaxi were significantly lower in the cases than in the controls: P = 0.03 and P = 0.02; OR = 1.67 (CI, 1.10-2.54) and OR = 1.75 (CI, 1.05-2.37). A similar trend was observed with Hmini but the difference did not reach the level of statistical significance: P = 0.06, OR = 1.57 (CI, 1.05-2.37). This study was repeated among cases and controls who had never taken HRT (respectively, n = 40 and n = 39). The results were similar. Among patients taking CS therapy, the presence of nontraumatic fractures was inversely related to BMD values but not to texture parameters. These data have shown that long-term CS therapy induces both BMD decrease and trabecular bone texture changes. The effect of CS therapy was much stronger on BMD than on the fractal H parameter. These results are in accordance with previous studies showing a lower effect of CS therapy on bone microarchitecture than on bone mass. These results can be contrasted with those observed in women with postmenopausal osteoporosis and vertebral crush fractures in which the variations in the fractal parameters are more significant than the BMD variations.
机译:骨矿物质密度(BMD)的降低和皮质类固醇诱导的骨质疏松症(CIOP)的微结构改变的相对作用受到了争论。我们的目标是评估皮质类固醇(CS)治疗患者的骨微结构(通过X射线照片上的纹理的分形分析)和BMD。在这项研究中,年龄匹配的患者和医院工作人员中有60名来自风湿病科的平均年龄为60.6 +/- 14.8岁的患者接受CS治疗超过6个月,泼尼松的累积剂量超过1 g,有57名对照。被招募。排除骨疾病和骨修饰药物(钙,维生素D和激素替代疗法[HRT]除外)。在18个方向进行定向分析后,在跟骨X射线照片上进行小梁骨纹理的分形分析。分形分析是基于分数布朗运动模型。结果由每个方向上的H参数(H = 2-分形维)表示,Hmean是18个方向的平均值,Hmini最小,Hmaxi最大。 BMD通过股骨颈(FN)和腰椎(LS)的双能X射线吸收法(DEXA)进行测量。计算出1个标准差的比值比(OR)。 CS治疗的平均持续时间和剂量为5.6 +/- 6.6年和16.9 +/- 19.7 g。 CS治疗与FN或LSBMD降低显着相关:OR = 1.95、95%置信区间(CI,1.29-2.97)和OR = 3.19(CI,1.80-5.66)。病例中的Hmean和Hmaxi显着低于对照组:P = 0.03和P = 0.02; OR = 1.67(CI,1.10-2.54)和OR = 1.75(CI,1.05-2.37)。 Hmini观察到了类似的趋势,但差异未达到统计学显着性水平:P = 0.06,OR = 1.57(CI,1.05-2.37)。在从未接受过HRT的病例和对照中重复了这项研究(分别为n = 40和n = 39)。结果相似。在接受CS治疗的患者中,非创伤性骨折的存在与BMD值成反比,但与质地参数却不成反比。这些数据表明,长期CS治疗可引起BMD降低和小梁骨纹理改变。 CS治疗对BMD的影响要强于分形H参数。这些结果与以前的研究结果一致,表明CS疗法对骨骼微结构的影响小于对骨骼质量的影响。这些结果可以与绝经后骨质疏松和椎体粉碎性骨折的女性所观察到的结果相比,后者的分形参数变化比BMD变化更显着。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号